Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846721 | 0.90 | CYP2C19 (0.49) | CYP2C19HTR1ATDP1CYP1A2LMNA | |
| SCHEMBL20416320 | 0.88 | CYP2C19 (0.47) | CYP2C19HTR1ATDP1CYP1A2LMNA | |
| SCHEMBL23691156 | 0.85 | ALDH1A1 (0.56) | CYP2C19HTR1ATDP1CYP1A2LMNA | |
| SCHEMBL21078258 | 0.83 | HTR1A (0.46) | CYP2C19HTR1ATDP1CYP1A2KDM4E | |
| SCHEMBL23567362 | 0.82 | ALDH1A1 (0.50) | CYP2C19HTR1ALMNAKDM4EALDH1A1 | |
| SCHEMBL13266483 | 0.82 | CYP2C19 (0.51) | CYP2C19TDP1LMNAALDH1A1MEN1 | |
| SCHEMBL11924531 | 0.81 | HSD17B10 (0.56) | CYP2C19HTR1ATDP1CYP1A2KDM4E | |
| SCHEMBL21730517 | 0.81 | CYP2C19 (0.60) | CYP2C19LMNAKDM4ECHRM1 | |
| SCHEMBL16435177 | 0.81 | HSD17B10 (0.56) | CYP2C19HTR1ATDP1CYP1A2KDM4E | |
| SCHEMBL30484009 | 0.79 | HTR1A (0.46) | CYP2C19HTR1ATDP1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3816164-B9 | ISOTHIAZOLO[5,4-D]PYRIMIDINE COMPOUND AS IRAK4 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2024-07-10 | — | — | EP | disclosed |
| EP-4273143-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Dalian WZ Probiotics AD Health Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-3778571-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | Bioway, Inc. (KR) | 2021-02-17 | — | — | EP | disclosed |
| US-20200157048-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | BIOWAY., INC (KR) | 2020-05-21 | — | — | US | disclosed |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2019190177-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | 주식회사 바이오웨이 | 2019-10-03 | — | — | WO | disclosed |
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9566283-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2015038778-A1 | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2012162025-A1 | METHODS OF SELECTING CANCER PATIENTS FOR TREATMENT WITH N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| WO-2010138820-A2 | N,N-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | CYP2C19 172/4885HTR1A 1338/4885TDP1 675/4885 |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | CYP2C19 4871/4885HTR1A 1472/4885TDP1 442/4885 |
| US-20200157048-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | PCK1, PCK2, ACACB | CYP2C19 4571/4885HTR1A 3578/4885TDP1 4412/4885 |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP2C19 2645/4885HTR1A 4235/4885TDP1 3378/4885 |
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | EIF2AK1, EIF2A, EIF4A2 | CYP2C19 4630/4885HTR1A 3636/4885TDP1 1923/4885 |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CYP2C19 2645/4885HTR1A 4235/4885TDP1 3378/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | CYP2C19 4871/4885HTR1A 1472/4885TDP1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.